Jump to content

Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial: Difference between revisions

From CAMIH
← Older edit
No edit summary
No edit summary
 
(36 intermediate revisions by 3 users not shown)
Line 2: Line 2:
|Reference=Publication: Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
|Reference=Publication: Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
}}
}}
{{Study Note}}
 
=Brief summary=
=Brief summary=
Cerebral edema is a common side effect in patients undergoing radiotherapy for brain tumors. In this study, researchers investigated the effect of Boswellia serrata H15 (BS-H15) on cerebral edema in patients undergoing radiotherapy for brain tumors. At the start of their radiotherapy, half of the patients took 4200mg/day of Boswellia serrata H15 and the other half took a placebo (consisting of lactose), which they continued throughout the duration of their radiotherapy. At the end of treatment, patients taking the BS-H15 had less cerebral edema than patients taking the sugar placebo. However, this positive effect of BS-H15 waned four weeks later. About a quarter of patients taking BS-H15 (6/22) have diarrhea during treatment.
Cerebral edema is a common side effect in patients undergoing radiotherapy for brain tumors. In this study, researchers investigated the effect of Boswellia serrata H15 (BS-H15) on cerebral edema in patients undergoing radiotherapy for brain tumors. At the start of their radiotherapy, half of the patients took 4200mg/day of Boswellia serrata H15 and the other half took a placebo (consisting of lactose), which they continued throughout the duration of their radiotherapy. At the end of treatment, patients taking the BS-H15 had less cerebral edema than patients taking the sugar placebo. However, this positive effect of BS-H15 waned four weeks later. About a quarter of patients taking BS-H15 (6/22) have diarrhea during treatment.
Line 21: Line 21:


{{RCT study general properties
{{RCT study general properties
|Inclusion criteria=Primary brain tumor/brain metastases
|Inclusion criteria=Primary brain tumor/brain metastases,
Radiotherapy of whole or part of the brain (>60% of brain irradiated) with a dose of 30-60 Gray in a fractionation of 5 " 1.8-3.0 Gray/week
Radiotherapy of whole or part of the brain (>60% of brain irradiated) with a dose of 30-60 Gray in a fractionation of 5 " 1.8-3.0 Gray/week,
No former radiotherapy in the brain
No former radiotherapy in the brain
|Exclusion criteria=Karnofsky index <50
|Exclusion criteria=Karnofsky index <50,
Dexamethasone >24 mg/day before radiotherapy
Dexamethasone >24 mg/day before radiotherapy
|N randomized=44
|N randomized=44
|Analysis=ITT Analysis
|Analysis=PP Analysis
|Specifications on analyses=Wilcoxon rank test  
|Specifications on analyses=Wilcoxon rank test  
2-sided testing
2-sided testing
|Countries of data collection=Germany
|Countries of data collection=Germany
|LoE=2b Oxford 2009
|LoE=2b Oxford 2009
|Outcome timeline=T0: Baseline at the beginning of radiotherapy  
|Outcome timeline=T0: Baseline at the beginning of radiotherapy,
T1: At the end of radiotherapy  
T1: At the end of radiotherapy,
Follow-up: After 4 weeks after end of radiotherapy
Follow-up: After 4 weeks end of radiotherapy
}}
}}
=Characteristics of participants=
=Characteristics of participants=


{{Characteristics of participants
{{Characteristics of participants
|Setting=Palliative
|Setting=Curative
|Types of cancer=Brain and Central Nervous System (CNS) Cancers - Glioblastoma
|Types of cancer=Brain and Central Nervous System (CNS) Cancers - Glioblastoma
|Stage cancer=NI
|Stage cancer=NI
Line 51: Line 51:
|Age groups=Adults (18+)
|Age groups=Adults (18+)
|Age groups specification=Mean value (range):
|Age groups specification=Mean value (range):
Intervention arm: 60 (32-74),  
Intervention arm: 60 years (32-74 years),  
Placebo arm: 58 (39-83)
Placebo arm: 58 years (39-83 years)
}}
}}
=Arms=
=Arms=
Line 59: Line 59:
|Arm type=Intervention
|Arm type=Intervention
|Number of participants (arm)=22
|Number of participants (arm)=22
|Drop-out=Allocated to Boswellia: n=22
|Drop-out=2
Received Boswellia: n=20
|Drop-out reasons=Could not swallow capsules n = 1
Did not receive Boswellia: N=2
Refused to swallow capsules n = 1
|Drop-out reasons=N=1 could not swallow capsules  
|Intervention=Boswellia capsule, dried extract: H15 (350 mg; Hecht Pharma, Stinstedt, Germany)
N=1 refused to swallow capsules
|Intervention=Boswellia capsule:
H15 (350 mg; Hecht Pharma, Stinstedt, Germany)
|Dosage and regime=4200 mg/day (3x4 capsules/day)
|Dosage and regime=4200 mg/day (3x4 capsules/day)
Starting with the first day of radiotherapy
Starting with the first day of radiotherapy,
Ending with the last day of radiotherapy
Ending with the last day of radiotherapy
|One-time application=No
|One-time application=No
Line 73: Line 70:
|Side Effects / Interactions=6 Patients reported minor gastrointestinal discomfort, Diarrhea (level 1-2)
|Side Effects / Interactions=6 Patients reported minor gastrointestinal discomfort, Diarrhea (level 1-2)
|Order number=1
|Order number=1
|Arm topic=Boswellia serrata
}}
}}
{{Arm
{{Arm
|Arm type=Placebo
|Arm type=Placebo
|Number of participants (arm)=22
|Number of participants (arm)=22
|Drop-out=Did not receive Placebo: n = 2
|Drop-out=2
|Drop-out reasons=n=1: refused to swallow capsules  
|Drop-out reasons=Refused to swallow capsules n = 1
n=1: epileptic seizure grade 4, discontinued therapy
Epileptic seizure grade 4, discontinued therapy n = 1
|Intervention=Placebo capsules (Lactose)
|Intervention=Placebo capsules (Lactose)
|Dosage and regime=84 capsules for 1 week (3x4 capsules/day starting with the first day of radiotherapy)
|Dosage and regime=84 capsules for 1 week (3x4 capsules/day starting with the first day of radiotherapy)
|One-time application=No
|One-time application=No
|Duration in days=-999
|Duration in days=-999
|Side Effects / Interactions=1 patient with nausea (grade 3), 1 patient with epileptic seizure (grade 4)
|Side Effects / Interactions=No side effects reported.
|Order number=1
|Order number=2
|Arm topic=Boswellia serrata
}}
}}
{{Arm Overview}}
{{Arm Overview}}
Line 91: Line 90:


{{Outcome
{{Outcome
|Outcome type=NI
|Outcome type=Primary
|Outcome name=Tumor progression
|Outcome specification=T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
|Type of measurement=MRI (Magnetic Resonance Imaging)
|Results during intervention=NA
|Results after intervention=Tumor volume: Significantly lower tumor volume in the Boswellia arm (2.9cm3) compared to the placebo arm (16.1cm3), p=0.008,
Tendentially fewer patients with progressive disease in Boswellia arm (0%) compared to placebo arm (18%)
Baseline: placebo: ratio = 0.11, intervention: ratio = 0.15
After radiotherapy: placebo: ratio = 0.15, intervention: ratio = 0.06
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=2
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Secondary
|Outcome name=Quality of life
|Outcome specification=NA
|Type of measurement=EORTC QLQ (European Organisation for Research and Treatment of Cancer Core/ Quality of Life questionnaire)
|Results during intervention=NA
|Results after intervention=Baseline: average score, placebo: 55.9 points, intervention: 54.3 points,
After radiotherapy: placebo: 56.2 points, intervention: 58.6 points,
Follow-up after 4 weeks: placebo: 53.8 points, intervention: 61.3 points
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=5
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Secondary
|Outcome name=Cognitive impairment
|Outcome specification=Mental Functioning
|Type of measurement=MMSE (Mini-Mental State Exam)
|Results during intervention=NA
|Results after intervention=Baseline: average score, placebo: 28 points, intervention: 29 points,
After radiotherapy: placebo: 28 points, intervention: 27 points,
Follow-up after 4 weeks: placebo: 26 points, intervention: 29 points
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=6
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Secondary
|Outcome name=PFS (Progression-Free Survival)
|Type of measurement=Observation
|Results during intervention=NA
|Results after intervention=No difference between the 2 arms, p = .68
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=4
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Primary
|Outcome name=Cerebral oedema
|Outcome name=Cerebral oedema
|Outcome specification=T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
|Outcome specification=T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
 
|Type of measurement=MRI (Magnetic Resonance Imaging)
Additional measurements:
Quality of Life: EORTC QLQ-30 questionnaire at baseline, after radiotherapy, and after 4 weeks of follow-up
Mental Functionin: mini-mental state test
Progression-free survival
Dexamethasone consumption (mg/week)
|Type of measurement=MRI (Magnetic Resonance Imaging), Observation
|Results during intervention=NA
|Results during intervention=NA
|Results after intervention=Volume of cerebral edema:  
|Results after intervention=Volume of cerebral edema: Significantly greater reduction of edema in the boswellia arm (reduction of 75%: 60% of patients) compared to the placebo arm (reduction of 75%: 26% of patients), p=0.023,
Significantly greater reduction of edema in the boswellia arm (reduction of 75%: 60% of patients) compared to the placebo arm (reduction of 75%: 26% of patients), p=0.023
Baseline: placebo: 188.4 mL (range, 0-617.3 mL), intervention: 159.3 mL (range, 0-506.2 mL)
 
After radiotherapy: placebo: 97.4 mL (range, 0-346.8 mL) intervention: 45.7 (range, 0-264.0 mL)
tumor volume
Follow-up after 4 weeks: placebo: 83.3 mL (range, 0-352.7 mL), intervention: 73.9 mL (range, 0-413.1 mL)
Significantly lower tumor volume in the Boswellia arm (2.9cm3) compared to the placebo arm (16.1cm3), p=0.008
 
tumor response (RECIST):  
Tendentially fewer patients with progressive disease in Boswellia arm (0%) compared to placebo arm (18%)
 
Additional results:
 
Progression-free survival rate: No differences between the arms
Quality of life: No differences between arms after radiation
Karnofsky index: No differences between the arms after radiation
Cognitive function:No differences between the arms after irradiation
Dexamethasone: No differences between arms during irradiation
|Bias arising from the randomization process=?
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
Line 127: Line 186:
|Overall RoB judgment=?
|Overall RoB judgment=?
|Order number=1
|Order number=1
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Primary
|Outcome name=Tumor response
|Outcome specification=T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
|Type of measurement=RECIST 1.0 Criteria (Response Evaluation Criteria in Solid Tumors)
|Results during intervention=NA
|Results after intervention=Tendency for fewer patients with progressive disease in boswellia (0%) compared to placebo (18%)
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=3
|Outcome topic=Boswellia serrata
}}
{{Outcome
|Outcome type=Secondary
|Outcome name=Additional medication
|Outcome specification=Dexamethasone
|Type of measurement=Observation
|Results during intervention=NA
|Results after intervention=No differences between the groups during irradiation (boswellia: 0-84mg/week; placebo: 0-112mg/week)
|Bias arising from the randomization process=?
|Bias due to deviation from intended intervention (assignment to intervention)=?
|Bias due to deviation from intended intervention (adhering to intervention)=NA
|Bias due to missing outcome data=?
|Bias in measurement of the outcome=?
|Bias in selection of the reported result=?
|Other sources of bias=?
|Overall RoB judgment=?
|Order number=7
|Outcome topic=Boswellia serrata
}}
}}
{{Outcome Overview}}
{{Outcome Overview}}
Line 138: Line 234:


{{Further points for assessing the study
{{Further points for assessing the study
|power analysis performed=?
|Sample size corresponds to power analysis=?
|Reasons given for samples being too small according to power analysis=?
|Samples sufficiently large=?
|Samples sufficiently large=?
|power analysis performed=?
|reasons given for samples being too small according to power analysis=?
|Ethnicity mentioned=?
|Ethnicity mentioned=?
|Other explanations for an effect besides the investigated intervention=?
|Possibility of attention effects=?
|Possibility of attention effects=?
|Possibility of placebo effects=?
|Possibility of placebo effects=?
|Other reasons=?
|Other reasons=?
|Testing for normal distribution=?
|Correct use of parametric and non-parametric tests=?
|Correct application of statistical tests=?
|Correction for multiple testing=?
|Correction for multiple testing=?
|Measurement of compliance=?
|Measurement of compliance=?
|Blinding reliable=?
|Check whether blinding was successful=?
|Consistent reporting in numbers=?
|Consistent reporting in numbers=?
|Comprehensive and coherent reporting=?
|Cross-over=?
|sufficient washout period=?
|sufficient washout period=?
|Tested for carry-over effects=?
|Tested for carry-over effects=?
|Were sequence effects tested=?
|Were sequence effects tested=?
|Comprehensive and coherent reporting=?
|Effect sizes reported=?
|Were side effects systematically recorded=?
|Were side effects systematically recorded=?
|Effect sizes reported=?
|Side effects taken into account in the interpretation of the results=?
|Side effects taken into account in the interpretation of the results=?
|Ethics / CoI / Funding=?
|Blinding reliable=?
|Check whether blinding was successful=?
|reasons given for samples being too small according to power analysis=?
|Testing for normal distribution=?
|Correct application of statistical tests=?
|mono- or multicentric=?
|mono- or multicentric=?
|Ethics / CoI / Funding=?
}}
}}
{{Additional Notes}}
{{Additional Notes}}

Latest revision as of 13:50, 29 November 2024


Reference ↗
Title Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
Topic Boswellia serrata
Author Kirste, S, Treier, M, Wehrle, SJ, Becker, G, Abdel-Tawab, M, Gerbeth, K, Hug, MJ, Lubrich, B, Grosu, AL, Momm, F
Year 2011
Journal Wiley Online Library
DOI https://doi.org/10.1002/cncr.25945

Brief summary

Cerebral edema is a common side effect in patients undergoing radiotherapy for brain tumors. In this study, researchers investigated the effect of Boswellia serrata H15 (BS-H15) on cerebral edema in patients undergoing radiotherapy for brain tumors. At the start of their radiotherapy, half of the patients took 4200mg/day of Boswellia serrata H15 and the other half took a placebo (consisting of lactose), which they continued throughout the duration of their radiotherapy. At the end of treatment, patients taking the BS-H15 had less cerebral edema than patients taking the sugar placebo. However, this positive effect of BS-H15 waned four weeks later. About a quarter of patients taking BS-H15 (6/22) have diarrhea during treatment.

Ein zerebrales Ödem ist eine häufige Nebenwirkung bei Patienten, die sich einer Strahlentherapie wegen Hirntumoren unterziehen. In dieser Studie untersuchten die Forscher die Wirkung von Boswellia serrata H15 (BS-H15) auf das zerebrale Ödem bei Patienten, die sich einer Strahlentherapie für Hirntumore unterziehen. Zu Beginn ihrer Strahlentherapie nahm die Hälfte der Patienten 4200mg/Tag Boswellia Serrata H15 und die andere Hälfte ein Placebo (bestehend aus der Milchzuckerlaktose) ein, dass sie während der gesamten Dauer ihrer Strahlentherapie fortsetzten. Am Ende der Behandlung hatten Patienten, die das BS-H15 einnahmen, weniger zerebrale Ödeme als Patienten, die das Zucker-Placebo einnahmen. Dieser positive Effekt des BS-H15 ließ jedoch vier Wochen später nach. Etwa ein Viertel der Patienten, die BS-H15 (6/22) einnehmen, haben während der Therapie Durchfall.

Study Design

Prospective / Retrospective Prospective: forward-looking, examples include clinical trials, cohort studies, and long-term observational studies;</br>Retrospective: backward-looking, relying on existing data, examples include case-control studies and retrospective cohort studies Prospective
Monocentric / Multicentric Monocentric: conducted in one center/ hospital; </br>Multicentric: conducted in multiple centers/ hospitals Monocentric
Blinding No: Open, all parties are aware of group assignments;</br>Single: one party is unaware of group assignments (generally participants);</br>Double: two parties are unaware of group assignments (generally the participants and the researchers); </br>Triple: concealing group assignment from additional parties Double
Is randomized Yes
Cross-over Participants alternate between different treatment groups or conditions over a specified period, allowing each participant to serve as their own control No
Number of arms 2

Study characteristics

Inclusion criteria Primary brain tumor/brain metastases,

Radiotherapy of whole or part of the brain (>60% of brain irradiated) with a dose of 30-60 Gray in a fractionation of 5 " 1.8-3.0 Gray/week, No former radiotherapy in the brain

Exclusion criteria Karnofsky index <50,

Dexamethasone >24 mg/day before radiotherapy

N randomized 44
Analysis PP: Per Protocol analysis, i.e. only participants included who adhered to the study protocol.</br>ITT: Intention-to-treat analysis, i.e. all randomized participants included regardless of any drop-outs or changes in assignment.</br>mITT: modified Intention-to-treat analysis can refer to analyses in which participants with missing outcome data are excluded or it can refer to analyses in which only participants who received at least one treatment dose are included. In this case, participants dropped out of the study prematurely for reasons unrelated to the treatment. PP Analysis
Specifications on analyses Wilcoxon rank test

2-sided testing

Countries of data collection Germany
LoE Level of evidence 2b Oxford 2009
Outcome timeline Data collection times T0: Baseline at the beginning of radiotherapy,

T1: At the end of radiotherapy, Follow-up: After 4 weeks end of radiotherapy

Characteristics of participants

Setting Refers to cancer therapy setting.</br>- Curative therapy: aims to completely eradicate a disease and achieve a full recovery; </br>- Neo-adjuvant therapy: form of curative therapy, given before the primary treatment for cancer (usually surgery); </br>- Adjuvant therapy: form of curative therapy, given after the primary treatment for cancer (usually surgery); </br>- Palliative therapy: focuses on providing relief from symptoms and improving the quality of life for patients, without necessarily targeting the underlying disease; </br>- Active surveillance: involves close monitoring of disease progression without any intervention (typically used for prostate cancer);</br>- No therapy setting: Patients who completed therapy/are currently not in cancer treatment, cancer survivors. Curative
Types of cancer "Other Cancers" means that only a subpopulation was specified, but further unspecified cancer types were included Brain and Central Nervous System (CNS) Cancers - Glioblastoma
Cancer stages Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;</br>Advanced Stage: cancer that has spread beyond its original site, mostly stages III and IV, with stage IV indicating distant metastasis NI
Specifications on cancer stages NI
Comorbidities NI
Current cancer therapies Radiation therapy
Specifications on cancer therapies Irradiation of the entire brain or at least 60 % with a dose of 30-60 Gray fractionated over 5 x 1.8-3.0 Gray/week
Previous cancer therapies NI
Gender Mixed
Gender specifications 45 % female
Age groups Adults (18+)
Age groups specification Mean value (range):

Intervention arm: 60 years (32-74 years), Placebo arm: 58 years (39-83 years)

Arms

Arm type Active control: group receives active treatment; </br>Passive control: for example treatment as usual, waiting control, no treatment Intervention
Number of participants (arm) N randomized 22
Drop-out Number of participants who left the study for any reason or did not provide information on every data collection date 2
Drop-out reasons Could not swallow capsules n = 1

Refused to swallow capsules n = 1

Intervention Boswellia capsule, dried extract: H15 (350 mg; Hecht Pharma, Stinstedt, Germany)
Dosage and regime 4200 mg/day (3x4 capsules/day)

Starting with the first day of radiotherapy, Ending with the last day of radiotherapy

One-time application No
Duration in days For long-term interventions, the number of days is an estimation.</br>A value of -999 indicates that the exact duration cannot be extracted from the study due to ambiguous or incomplete information. See Outcome timeline or Dosage and regime for further information. -999
Side effects / Interactions 6 Patients reported minor gastrointestinal discomfort, Diarrhea (level 1-2)
Arm type Active control: group receives active treatment; </br>Passive control: for example treatment as usual, waiting control, no treatment Placebo
Number of participants (arm) N randomized 22
Drop-out Number of participants who left the study for any reason or did not provide information on every data collection date 2
Drop-out reasons Refused to swallow capsules n = 1

Epileptic seizure grade 4, discontinued therapy n = 1

Intervention Placebo capsules (Lactose)
Dosage and regime 84 capsules for 1 week (3x4 capsules/day starting with the first day of radiotherapy)
One-time application No
Duration in days For long-term interventions, the number of days is an estimation.</br>A value of -999 indicates that the exact duration cannot be extracted from the study due to ambiguous or incomplete information. See Outcome timeline or Dosage and regime for further information. -999
Side effects / Interactions No side effects reported.

Outcomes

Cerebral oedema

Outcome type As specificed by the authors Primary
Outcome specification T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
Type of measurement MRI (Magnetic Resonance Imaging)
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". Volume of cerebral edema: Significantly greater reduction of edema in the boswellia arm (reduction of 75%: 60% of patients) compared to the placebo arm (reduction of 75%: 26% of patients), p=0.023,

Baseline: placebo: 188.4 mL (range, 0-617.3 mL), intervention: 159.3 mL (range, 0-506.2 mL) After radiotherapy: placebo: 97.4 mL (range, 0-346.8 mL) intervention: 45.7 (range, 0-264.0 mL) Follow-up after 4 weeks: placebo: 83.3 mL (range, 0-352.7 mL), intervention: 73.9 mL (range, 0-413.1 mL)

Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Tumor progression

Outcome type As specificed by the authors Primary
Outcome specification T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
Type of measurement MRI (Magnetic Resonance Imaging)
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". Tumor volume: Significantly lower tumor volume in the Boswellia arm (2.9cm3) compared to the placebo arm (16.1cm3), p=0.008,

Tendentially fewer patients with progressive disease in Boswellia arm (0%) compared to placebo arm (18%) Baseline: placebo: ratio = 0.11, intervention: ratio = 0.15 After radiotherapy: placebo: ratio = 0.15, intervention: ratio = 0.06

Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Tumor response

Outcome type As specificed by the authors Primary
Outcome specification T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline
Type of measurement RECIST 1.0 Criteria (Response Evaluation Criteria in Solid Tumors)
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". Tendency for fewer patients with progressive disease in boswellia (0%) compared to placebo (18%)
Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

PFS (Progression-Free Survival)

Outcome type As specificed by the authors Secondary
Outcome specification
Type of measurement Observation
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". No difference between the 2 arms, p = .68
Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Quality of life

Outcome type As specificed by the authors Secondary
Outcome specification NA
Type of measurement EORTC QLQ (European Organisation for Research and Treatment of Cancer Core/ Quality of Life questionnaire)
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". Baseline: average score, placebo: 55.9 points, intervention: 54.3 points,

After radiotherapy: placebo: 56.2 points, intervention: 58.6 points, Follow-up after 4 weeks: placebo: 53.8 points, intervention: 61.3 points

Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Cognitive impairment

Outcome type As specificed by the authors Secondary
Outcome specification Mental Functioning
Type of measurement MMSE (Mini-Mental State Exam)
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". Baseline: average score, placebo: 28 points, intervention: 29 points,

After radiotherapy: placebo: 28 points, intervention: 27 points, Follow-up after 4 weeks: placebo: 26 points, intervention: 29 points

Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Additional medication

Outcome type As specificed by the authors Secondary
Outcome specification Dexamethasone
Type of measurement Observation
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". NA
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". No differences between the groups during irradiation (boswellia: 0-84mg/week; placebo: 0-112mg/week)
Risk of Bias Assessment: Cochrane RoB tool 2.0
Bias arising from the randomization process ?
Bias due to deviation from intended intervention (assignment to intervention) ?
Bias due to deviation from intended intervention (adhering to intervention) NA
Bias due to missing outcome data ?
Bias in measurement of the outcome ?
Bias in selection of the reported result ?
Other sources of bias ?
Overall RoB judgment ?

Funding and Conflicts of Interest

Funding No information on financing.
Conflicts of Interest No information on conflicts of interest.

Further points for assessing the study

Sample

Power analysis performed ?
- Sample size corresponds to power analysis ?
- Reasons for insufficient sample size based on power analysis ?
If no power analysis performed: at least moderate sample size (n >= 30 per arm) ?
Ethnicity mentioned ?

Alternative Explanation

Other explanations for an effect besides the investigated intervention ?
- Possibility of attention effects ?
- Possibility of placebo effects ?
- Other reasons ?

Statistics

Correct use of parametric and non-parametric tests Testing for normal distribution only necessary if parametric tests are used, NI: use of parametric tests without report of normal distribution testing ?
Correction for multiple testing ?
Measurement of compliance ?
Consistent reporting in numbers (figures, flowchart, abstract, results) ?
Comprehensive and coherent reporting ?
Cross-over ?
- Sufficient washout period ?
- Tested for carry-over effects ?
- Tested for sequence effects ?

Interpretation of results

Effect sizes reported (clinical vs. statistical significance) ?
Side effects systematically recorded ?
Side effects considered in result interpretation ?
Ethics votum ?


Additional Notes

Retrieved from "https://camih.med.uni-jena.de/camih/index.php?title=Kirste_et_al._(2011):_Boswellia_serrata_Acts_on_Cerebral_Edema_in_Patients_Irradiated_for_Brain_Tumors._A_Prospective,_Randomized,_Placebo-Controlled,_Double-Blind_Pilot_Trial&oldid=7414"